TY - JOUR
T1 - A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant
T2 - Analysis of the FIRST trial
AU - Dumontet, Charles
AU - Hulin, Cyrille
AU - Dimopoulos, Meletios A.
AU - Belch, Andrew
AU - Dispenzieri, Angela
AU - Ludwig, Heinz
AU - Rodon, Philippe
AU - Van Droogenbroeck, Jan
AU - Qiu, Lugui
AU - Cavo, Michele
AU - Van De Velde, Ann
AU - Lahuerta, Juan José
AU - Allangba, Olivier
AU - Lee, Jae Hoon
AU - Boyle, Eileen
AU - Perrot, Aurore
AU - Moreau, Philippe
AU - Manier, Salomon
AU - Attal, Michel
AU - Roussel, Murielle
AU - Mohty, Mohamad
AU - Mary, Jean Yves
AU - Civet, Alexandre
AU - Costa, Bruno
AU - Tinel, Antoine
AU - Gaston-Mathé, Yann
AU - Facon, Thierry
N1 - Publisher Copyright:
© 2018 The Author(s).
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Infections are a major cause of death in patients with multiple myeloma. A post hoc analysis of the phase 3 FIRST trial was conducted to characterize treatment-emergent (TE) infections and study risk factors for TE grade ≥ 3 infection. The number of TE infections/month was highest during the first 4 months of treatment (defined as early infection). Of 1613 treated patients, 340 (21.1%) experienced TE grade ≥ 3 infections in the first 18 months and 56.2% of these patients experienced their first grade ≥ 3 infection in the first 4 months. Risk of early infection was similar regardless of treatment. Based on the analyses of data in 1378 patients through multivariate logistic regression, a predictive model of first TE grade ≥ 3 infection in the first 4 months retained Eastern Cooperative Oncology Group performance status and serum β 2 -microglobulin, lactate dehydrogenase, and hemoglobin levels to define high- and low-risk groups showing significantly different rates of infection (24.0% vs. 7.0%, respectively; P < 0.0001). The predictive model was validated with data from three clinical trials. This predictive model of early TE grade ≥ 3 infection may be applied in the clinical setting to guide infection monitoring and strategies for infection prevention.
AB - Infections are a major cause of death in patients with multiple myeloma. A post hoc analysis of the phase 3 FIRST trial was conducted to characterize treatment-emergent (TE) infections and study risk factors for TE grade ≥ 3 infection. The number of TE infections/month was highest during the first 4 months of treatment (defined as early infection). Of 1613 treated patients, 340 (21.1%) experienced TE grade ≥ 3 infections in the first 18 months and 56.2% of these patients experienced their first grade ≥ 3 infection in the first 4 months. Risk of early infection was similar regardless of treatment. Based on the analyses of data in 1378 patients through multivariate logistic regression, a predictive model of first TE grade ≥ 3 infection in the first 4 months retained Eastern Cooperative Oncology Group performance status and serum β 2 -microglobulin, lactate dehydrogenase, and hemoglobin levels to define high- and low-risk groups showing significantly different rates of infection (24.0% vs. 7.0%, respectively; P < 0.0001). The predictive model was validated with data from three clinical trials. This predictive model of early TE grade ≥ 3 infection may be applied in the clinical setting to guide infection monitoring and strategies for infection prevention.
UR - http://www.scopus.com/inward/record.url?scp=85047203048&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047203048&partnerID=8YFLogxK
U2 - 10.1038/s41375-018-0133-x
DO - 10.1038/s41375-018-0133-x
M3 - Article
C2 - 29784907
AN - SCOPUS:85047203048
SN - 0887-6924
VL - 32
SP - 1404
EP - 1413
JO - Leukemia
JF - Leukemia
IS - 6
ER -